Bayer submits cancer drug for market authorisation in Japan

FRANKFURT Fri Dec 21, 2012 2:10am EST

Related Topics

FRANKFURT Dec 21 (Reuters) - Germany's Bayer has submitted its cancer drug regorafenib, used for the treatment of gastrointestinal stromal tumors, for market authorisation in Japan, it said on Friday. (Reporting by Christoph Steitz)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.